INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Systematic review / meta-analysis / 2024

Semaglutide reduced weight mostly via fat mass loss, but lean mass reductions accounted for nearly 0% to 40% of total weight lost across studies.

A systematic review examined 6 studies encompassing 1,541 overweight or obese adults with or without type 2 diabetes to assess semaglutide's impact on lean body mass. Significant weight reductions were driven mainly by fat mass loss. Lean mass remained stable in some instances, but in others, reductions ranged from almost 0% to 40% of total weight reduction, particularly in larger trials. However, the proportion of lean mass relative to total body mass increased.

Study type
Systematic review of RCTs and observational studies
Who was studied
1,541 overweight or obese adults (with or without type 2 diabetes)
What was measured
Lean body mass and fat mass changes during weight loss

THE PAPER

A systematic review of the effect of semaglutide on lean mass: insights from clinical trials.

Bikou A, Dermiki-Gkana F, Penteris M, Constantinides TK, Kontogiorgis C. Expert Opin Pharmacother, 2024.

PubMed 38629387 ↗DOI 10.1080/14656566.2024.2343092 ↗

Diabetes & blood sugarWeight & appetite

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.